Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 39,600 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 39,600 shares of the stock in a transaction on Monday, October 6th. The stock was sold at an average price of $18.06, for a total transaction of $715,176.00. Following the completion of the sale, the chief operating officer owned 205,541 shares in the company, valued at approximately $3,712,070.46. This trade represents a 16.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Ryan Cohlhepp also recently made the following trade(s):

• On Tuesday, October 7th, Ryan Cohlhepp sold 10,900 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.06, for a total transaction of $196,854.00.

Bicara Therapeutics Stock Performance

BCAX opened at $18.00 on Thursday. The firm’s fifty day moving average is $12.22 and its two-hundred day moving average is $11.80. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $28.09. The firm has a market cap of $982.98 million and a PE ratio of -5.68.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.04. Equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicara Therapeutics in a research report on Saturday, September 27th. Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. Piper Sandler assumed coverage on shares of Bicara Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price objective for the company. Finally, HC Wainwright lowered their price objective on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.86.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd grew its position in Bicara Therapeutics by 4.1% in the first quarter. XTX Topco Ltd now owns 28,453 shares of the company’s stock valued at $371,000 after purchasing an additional 1,119 shares in the last quarter. Legal & General Group Plc grew its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares in the last quarter. California State Teachers Retirement System bought a new position in Bicara Therapeutics in the fourth quarter valued at $25,000. Ameritas Investment Partners Inc. lifted its stake in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after acquiring an additional 1,474 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Bicara Therapeutics by 4.8% in the first quarter. Bank of New York Mellon Corp now owns 42,192 shares of the company’s stock valued at $550,000 after acquiring an additional 1,924 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.